Adaptive Ev To Free Cash Flow vs Free Cash Flow Yield Analysis

ADPT Stock

USD 6.38 0.33 4.92%

Adaptive Biotechnologies financial indicator trend analysis is way more than just evaluating Adaptive Biotechnologies prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Adaptive Biotechnologies is a good investment. Please check the relationship between Adaptive Biotechnologies Ev To Free Cash Flow and its Free Cash Flow Yield accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptive Biotechnologies Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

Ev To Free Cash Flow vs Free Cash Flow Yield

Ev To Free Cash Flow vs Free Cash Flow Yield Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Adaptive Biotechnologies Ev To Free Cash Flow account and Free Cash Flow Yield. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Adaptive Biotechnologies' Ev To Free Cash Flow and Free Cash Flow Yield is -0.53. Overlapping area represents the amount of variation of Ev To Free Cash Flow that can explain the historical movement of Free Cash Flow Yield in the same time period over historical financial statements of Adaptive Biotechnologies Corp, assuming nothing else is changed. The correlation between historical values of Adaptive Biotechnologies' Ev To Free Cash Flow and Free Cash Flow Yield is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ev To Free Cash Flow of Adaptive Biotechnologies Corp are associated (or correlated) with its Free Cash Flow Yield. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Yield has no effect on the direction of Ev To Free Cash Flow i.e., Adaptive Biotechnologies' Ev To Free Cash Flow and Free Cash Flow Yield go up and down completely randomly.

Correlation Coefficient

-0.53

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Ev To Free Cash Flow

A valuation metric comparing the company's enterprise value to its free cash flow, used to evaluate whether a company is undervalued or overvalued.

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Most indicators from Adaptive Biotechnologies' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Adaptive Biotechnologies current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptive Biotechnologies Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

Selling General Administrative is likely to drop to about 57.1 M in 2024. Sales General And Administrative To Revenue is likely to drop to 0.35 in 2024

	2021	2022	2023	2024 (projected)
Gross Profit	105.0M	127.4M	94.7M	82.4M
Total Revenue	154.3M	185.3M	170.3M	123.7M

Gross Profit Total Revenue

Adaptive Biotechnologies fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Inventory
Total Assets		0.95	0.95	0.99	0.87	0.97	0.89	0.98	0.52	-0.64	0.61	0.69	0.9	0.72	0.49	-0.37	0.95	0.56	-0.27	0.92	0.44	0.93	0.92	-0.95	0.89	0.86
Other Current Liab	0.95		0.98	0.95	0.81	0.94	0.97	0.97	0.59	-0.74	0.68	0.62	0.92	0.76	0.31	-0.41	0.86	0.67	-0.29	0.93	0.63	0.83	0.91	-0.94	0.92	0.95
Total Current Liabilities	0.95	0.98		0.97	0.88	0.97	0.98	0.98	0.64	-0.8	0.76	0.6	0.91	0.83	0.36	-0.45	0.86	0.75	-0.34	0.97	0.64	0.84	0.96	-0.98	0.97	0.96
Total Stockholder Equity	0.99	0.95	0.97		0.9	0.99	0.9	0.99	0.54	-0.67	0.66	0.66	0.91	0.75	0.51	-0.38	0.94	0.61	-0.27	0.95	0.45	0.91	0.94	-0.97	0.93	0.88
Other Liab	0.87	0.81	0.88	0.9		0.93	0.79	0.86	0.66	-0.74	0.85	0.3	0.67	0.84	0.64	-0.47	0.88	0.77	-0.36	0.94	0.36	0.9	0.93	-0.92	0.92	0.76
Net Tangible Assets	0.97	0.94	0.97	0.99	0.93		0.91	0.98	0.61	-0.72	0.72	0.59	0.89	0.8	0.5	-0.42	0.91	0.68	-0.31	0.98	0.5	0.9	0.96	-0.98	0.96	0.9
Property Plant And Equipment Net	0.89	0.97	0.98	0.9	0.79	0.91		0.94	0.65	-0.82	0.75	0.59	0.9	0.8	0.18	-0.43	0.76	0.78	-0.32	0.94	0.76	0.73	0.9	-0.93	0.95	0.97
Current Deferred Revenue	0.98	0.97	0.98	0.99	0.86	0.98	0.94		0.56	-0.71	0.66	0.69	0.95	0.76	0.44	-0.39	0.88	0.64	-0.28	0.95	0.53	0.85	0.94	-0.98	0.93	0.93
Net Debt	0.52	0.59	0.64	0.54	0.66	0.61	0.65	0.56		-0.95	0.77	0.05	0.45	0.95	0.11	-0.93	0.46	0.77	-0.88	0.7	0.67	0.49	0.78	-0.69	0.72	0.68
Retained Earnings	-0.64	-0.74	-0.8	-0.67	-0.74	-0.72	-0.82	-0.71	-0.95		-0.87	-0.2	-0.61	-0.97	-0.12	0.8	-0.54	-0.9	0.74	-0.82	-0.78	-0.55	-0.86	0.8	-0.85	-0.82
Accounts Payable	0.61	0.68	0.76	0.66	0.85	0.72	0.75	0.66	0.77	-0.87		0.03	0.45	0.87	0.32	-0.53	0.6	0.98	-0.45	0.83	0.58	0.64	0.81	-0.76	0.85	0.7
Cash	0.69	0.62	0.6	0.66	0.3	0.59	0.59	0.69	0.05	-0.2	0.03		0.82	0.24	0.16	-0.04	0.56	0.05	0.0	0.48	0.29	0.47	0.48	-0.57	0.45	0.56
Non Current Assets Total	0.9	0.92	0.91	0.91	0.67	0.89	0.9	0.95	0.45	-0.61	0.45	0.82		0.63	0.31	-0.33	0.74	0.47	-0.23	0.84	0.54	0.68	0.83	-0.9	0.82	0.92
Non Currrent Assets Other	0.72	0.76	0.83	0.75	0.84	0.8	0.8	0.76	0.95	-0.97	0.87	0.24	0.63		0.32	-0.84	0.67	0.85	-0.76	0.87	0.63	0.68	0.93	-0.87	0.87	0.81
Other Assets	0.49	0.31	0.36	0.51	0.64	0.5	0.18	0.44	0.11	-0.12	0.32	0.16	0.31	0.32		-0.13	0.57	0.17	-0.06	0.43	-0.45	0.59	0.48	-0.49	0.36	0.19
Long Term Debt	-0.37	-0.41	-0.45	-0.38	-0.47	-0.42	-0.43	-0.39	-0.93	0.8	-0.53	-0.04	-0.33	-0.84	-0.13		-0.33	-0.52	0.99	-0.49	-0.46	-0.35	-0.64	0.53	-0.49	-0.49
Cash And Short Term Investments	0.95	0.86	0.86	0.94	0.88	0.91	0.76	0.88	0.46	-0.54	0.6	0.56	0.74	0.67	0.57	-0.33		0.5	-0.23	0.85	0.29	0.99	0.85	-0.86	0.81	0.7
Net Receivables	0.56	0.67	0.75	0.61	0.77	0.68	0.78	0.64	0.77	-0.9	0.98	0.05	0.47	0.85	0.17	-0.52	0.5		-0.44	0.8	0.7	0.53	0.77	-0.73	0.84	0.73
Good Will	-0.27	-0.29	-0.34	-0.27	-0.36	-0.31	-0.32	-0.28	-0.88	0.74	-0.45	0.0	-0.23	-0.76	-0.06	0.99	-0.23	-0.44		-0.37	-0.42	-0.25	-0.54	0.42	-0.38	-0.37
Common Stock Total Equity	0.92	0.93	0.97	0.95	0.94	0.98	0.94	0.95	0.7	-0.82	0.83	0.48	0.84	0.87	0.43	-0.49	0.85	0.8	-0.37		0.59	0.84	0.97	-0.98	1.0	0.92
Common Stock Shares Outstanding	0.44	0.63	0.64	0.45	0.36	0.5	0.76	0.53	0.67	-0.78	0.58	0.29	0.54	0.63	-0.45	-0.46	0.29	0.7	-0.42	0.59		0.27	0.55	-0.54	0.66	0.74
Short Term Investments	0.93	0.83	0.84	0.91	0.9	0.9	0.73	0.85	0.49	-0.55	0.64	0.47	0.68	0.68	0.59	-0.35	0.99	0.53	-0.25	0.84	0.27		0.85	-0.84	0.8	0.67
Long Term Debt Total	0.92	0.91	0.96	0.94	0.93	0.96	0.9	0.94	0.78	-0.86	0.81	0.48	0.83	0.93	0.48	-0.64	0.85	0.77	-0.54	0.97	0.55	0.85		-0.99	0.96	0.9
Non Current Liabilities Total	-0.95	-0.94	-0.98	-0.97	-0.92	-0.98	-0.93	-0.98	-0.69	0.8	-0.76	-0.57	-0.9	-0.87	-0.49	0.53	-0.86	-0.73	0.42	-0.98	-0.54	-0.84	-0.99		-0.97	-0.93
Capital Surpluse	0.89	0.92	0.97	0.93	0.92	0.96	0.95	0.93	0.72	-0.85	0.85	0.45	0.82	0.87	0.36	-0.49	0.81	0.84	-0.38	1.0	0.66	0.8	0.96	-0.97		0.93
Inventory	0.86	0.95	0.96	0.88	0.76	0.9	0.97	0.93	0.68	-0.82	0.7	0.56	0.92	0.81	0.19	-0.49	0.7	0.73	-0.37	0.92	0.74	0.67	0.9	-0.93	0.93

Click cells to compare fundamentals

Adaptive Biotechnologies Account Relationship Matchups

Adaptive Biotechnologies fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	912.3M	1.1B	923.3M	856.6M	661.1M	811.6M
Other Current Liab	12.9M	19.8M	19.5M	18.9M	12.8M	15.3M
Total Current Liabilities	78.3M	105.2M	113.8M	109.8M	88.0M	84.7M
Total Stockholder Equity	571.0M	743.3M	604.0M	464.2M	308.4M	347.0M
Other Liab	226.3M	163.6M	98.8M	184.0M	211.6M	125.4M
Net Tangible Assets	440.1M	614.1M	476.5M	338.4M	389.1M	205.2M
Property Plant And Equipment Net	60.4M	139.0M	172.9M	164.2M	120.3M	108.4M
Current Deferred Revenue	61.0M	73.3M	80.5M	64.1M	48.6M	55.7M
Net Debt	(60.0M)	(15.6M)	(27.3M)	18.0M	164.4M	172.6M
Retained Earnings	(365.5M)	(511.6M)	(718.9M)	(919.1M)	(1.1B)	(1.1B)
Accounts Payable	4.5M	3.2M	3.3M	8.1M	7.7M	4.8M
Cash	96.6M	123.4M	139.1M	90.0M	65.1M	102.9M
Non Current Assets Total	299.6M	389.5M	520.6M	294.5M	250.9M	324.4M
Non Currrent Assets Other	2.9M	2.7M	3.0M	4.5M	6.5M	6.8M
Other Assets	39.5M	2.7M	3.0M	4.5M	4.0M	6.7M
Cash And Short Term Investments	576.9M	688.3M	353.1M	498.2M	346.4M	443.1M
Net Receivables	12.7M	10.0M	17.4M	40.1M	38.0M	20.2M
Common Stock Shares Outstanding	69.2M	131.2M	140.4M	142.5M	144.4M	131.8M
Short Term Investments	480.3M	564.8M	214.0M	408.2M	281.3M	340.3M
Liabilities And Stockholders Equity	912.3M	1.1B	923.3M	856.6M	661.1M	811.6M
Non Current Liabilities Total	263.0M	268.0M	205.4M	282.7M	264.8M	276.3M
Capital Surpluse	935.8M	1.3B	1.3B	1.4B	1.6B	910.1M
Inventory	9.1M	14.1M	19.3M	14.5M	14.4M	13.2M
Other Current Assets	14.1M	14.5M	13.0M	9.4M	11.4M	10.7M
Other Stockholder Equity	23.5M	1.3B	1.3B	1.4B	1.5B	865.0M
Total Liab	341.3M	373.1M	319.2M	392.5M	352.9M	337.9M
Net Invested Capital	571.0M	743.3M	604.0M	464.2M	308.4M	347.0M
Property Plant And Equipment Gross	60.4M	139.0M	172.9M	164.2M	193.6M	119.9M
Total Current Assets	612.7M	726.9M	402.7M	562.1M	410.2M	487.2M
Accumulated Other Comprehensive Income	671K	893K	(1.1M)	(4.1M)	215K	225.8K
Net Working Capital	534.4M	621.7M	288.9M	452.4M	322.2M	402.6M
Intangible Assets	11.9M	10.2M	8.5M	6.8M	5.1M	8.2M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Adaptive Stock Analysis

When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC